Fragment designation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-15. Numbers and descriptions here follow the published literature rather than marketing material.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
Commercial airliners typically cruise at altitudes of 9–12 km (30,000–39,000 ft) which is in the lower reaches of the stratosphere in temperate latitudes. This optimizes fuel efficiency, mostly due to the low temperatures encountered near the tropopause and low air density, reducing parasitic drag on the airframe. Stated another way, it allows the airliner to fly faster while maintaining lift equal to the weight of the plane. (The fuel consumption depends on the drag, which is related to the lift by the lift-to-drag ratio.) It also allows the airplane to stay above the turbulent weather of the troposphere. The Concorde aircraft cruised at Mach 2 at about 60,000 ft (18 km), and the SR-71 cruised at Mach 3 at 85,000 ft (26 km), all within the stratosphere. Because the temperature in the tropopause and lower stratosphere is largely constant with increasing altitude, very little convection and its resultant turbulence occurs there. Most turbulence at this altitude is caused by variations in the jet stream and other local wind shears, although areas of significant convective activity (thunderstorms) in the troposphere below may produce turbulence as a result of convective overshoot. On October 24, 2014, Alan Eustace became the record holder for reaching the altitude record for a manned balloon at 135,890 ft (41,419 m). Eustace also broke the world records for vertical speed skydiving, reached with a peak velocity of 1,321 km/h (822 mph) and total freefall distance of 123,414 ft (37,617 m), lasting 4 minutes and 27 seconds.
For example, advanced glycation end products (AGEs), which are more prevalent in hyperglycemic conditions, can interfere with the normal function of the immune system and contribute to the pathogenesis of infections. AGEs, whose cross-links are permanent will continue to harm the surrounding tissue until the proteins are destroyed. In addition, they can interact with the RAGE receptor to cause oxidative stress, apoptosis, and inflammation. Due to neutrophil changes, microbiological changes, and chronic inflammation, patients with hyperglycemia are thus more prone to severe respiratory infections. This increased risk is particularly pronounced with pathogens like Mycobacterium tuberculosis (the bacterium responsible for tuberculosis) and the flu. Hyperglycemic individuals have also responded more severely to the symptoms of COVID-19. Another example is diabetes. Hyperglycemia and risk of severe infectious outcomes can even further be complicated by physiological stress. For instance, elevated blood glucose levels can actively contribute to pathophysiology of this disease, by exacerbating existing inflammation, impairing cellular immune responses, and increasing oxidative stress, which can also lead to more severe infection. In addition, patients with acute hyperglycemia who don't have a history of diabetes can experience higher rates of mortality and complications. Postprandial hyperglycemic levels as high as 8.6 mmol/L (155 mg/dL) at 1-h are associated with T2DM-related complications, which worsen as the degree of hyperglycemia increases.
=== Hyperaldosteronism === Primary aldosteronism, also known as primary hyperaldosteronism, is characterized by the overproduction of aldosterone by the adrenal glands, when not a result of excessive renin secretion. It leads to arterial hypertension (high blood pressure) associated with hypokalemia, usually a diagnostic clue. Secondary hyperaldosteronism, on the other hand, is due to overactivity of the renin–angiotensin system. Conn's syndrome is primary hyperaldosteronism caused by an aldosterone-producing adenoma. Depending on cause and other factors, hyperaldosteronism can be treated by surgery and/or medically, such as by aldosterone antagonists. The ratio of renin to aldosterone is an effective screening test to screen for primary hyperaldosteronism related to adrenal adenomas. It is the most sensitive serum blood test to differentiate primary from secondary causes of hyperaldosteronism. Blood obtained when the patient has been standing for more than 2 hours are more sensitive than those from when the patient is lying down. Before the test, individuals should not restrict salt and low potassium should be corrected before the test because it can suppress aldosterone secretion.
Cellular thermal shift assay (CETSA®) is a biophysical technique applicable on living cells as well as tissue biopsies. CETSA® is based on the discovery that protein melting curves can also be generated in intact cells and that drug binding leads to very significant thermal stabilization of proteins. Upon denaturation, proteins are aggregated and can thus be removed by centrifugation after lysis of the cells. The stable proteins are found in the supernatant can be detected; e.g., by western blot, alpha-LISA, or mass spectrometry. The CETSA®-technique is highly stringent, reproducible, and not prone to false positives. However, it is possible for a sample, or small molecule compound, to bind a protein in a given target's pathway. If that protein induces further stabilization of the original target protein through a cascade event, it could manifest as direct target engagement. An advantage of this method is that it is label-free and thus applicable for studies of drug binding in a wide range of cells and tissues. CETSA® can also be conducted on cell lysates versus intact cells, helping to determine sample penetration of the cell membrane.
== Synthesis == The glycosylation of proteins has an array of different applications from influencing cell to cell communication to changing the thermal stability and the folding of proteins. Due to the unique abilities of glycoproteins, they can be used in many therapies. By understanding glycoproteins and their synthesis, they can be made to treat cancer, Crohn's Disease, high cholesterol, and more. The process of glycosylation (binding a carbohydrate to a protein) is a post-translational modification, meaning it happens after the production of the protein. Glycosylation is a process that roughly half of all human proteins undergo and heavily influences the properties and functions of the protein. Within the cell, glycosylation occurs in the endoplasmic reticulum.
Sources: en.wikipedia.org
=== 2011–2017: The Only Way Is Essex, I'm a Celebrity...Get Me Out of Here! and Celebrity Big Brother === In January 2011, Julie Childs, mother of Collins' friend Amy, suggested to producers of the ITV2 reality series The Only Way Is Essex that Collins would be an appropriate subject. They visited Collins' house and subsequently filmed her and her friends for two weeks. After returning to work as a car sales executive for a week, she was cast in the programme and began appearing in The Only Way Is Essex from its second series beginning in March 2011. Her first scene saw her attempting to sell a car to Kirk Norcross and taking him for a test drive. Collins ultimately quit her job to appear on the programme full time, and was paid £50 a day for her early appearances on the show, which she described as a "massive risk". Her mother Joan joined the programme during the fifth series in April 2012. From September 2011 until March 2013, Collins wrote a regular column in the tabloid magazine Closer. In April 2013, she released her debut autobiography Basically...: My Life as a Real Essex Girl, which became a bestseller in its first week of release. In January 2014, Collins took part in the second series of the ITV diving competition Splash!. During training, Collins suffered severe bruising and admitted she had to overcome a fear of water. She became the third celebrity to be eliminated after losing the splash-off to Michaela Strachan in the first heat. In November 2014, she took part in the fourteenth series of I'm a Celebrity...Get Me Out of Here! on ITV.
=== Pregnancy and breastfeeding === Benzodiazepines cross the placenta, enter the fetus, and are also excreted in breast milk. The use of alprazolam during pregnancy is associated with congenital abnormalities, and use in the last trimester may cause fetal drug dependence and withdrawal symptoms in the post-natal period as well as neonatal flaccidity and respiratory problems. However, in long-term users of benzodiazepines, abrupt discontinuation due to concerns of teratogenesis has a high risk of causing extreme withdrawal symptoms and a severe rebound effect of the underlying mental health disorder. Spontaneous abortions may also result from abrupt withdrawal of psychotropic medications, including benzodiazepines.
Some countries require or recommend fortification of grain foods such as wheat, rice or maize (corn) because processing lowers vitamin content. As of February 2022, 59 countries, mostly in North and Sub-Saharan Africa, require food fortification of wheat, rice or maize with thiamine or thiamine mononitrate. The amounts stipulated range from 2.0 to 10.0 mg/kg. An additional 18 countries have a voluntary fortification program. For example, the Indian government recommends 3.5 mg/kg for "maida" (white) and "atta" (whole wheat) flour.
Reactive proteins composed of native amino acids that meet these criteria can be termed Click biology reactions, by analogy to the efficient organic reactions of Click chemistry. Examples of Click biology for bioconjugation include HaloTag with alkyl halides, SNAP-tag with O-benzyl guanine, SpyTag with SpyCatcher, and split intein reconstitution.
The right-hand side strictly vanishes for a flat geometry only. As a consequence, the integral form of the continuity equation is difficult to define and not necessarily valid for a region within which spacetime is significantly curved (e.g. around a black hole, or across the whole universe).
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.